Home | Publications | Company Information | Top 50 Pharma | Shire place holder
place holder place holder

Shire

Shire: Pipeline | Products | Performance | Potential


Publication Date   May 2008
Publisher   Espicom
Product Type   Report
Pages   76
ISBN Number   not applicable
Product Code   ESP1094
Ask a question about this product?

Price £595.00

approximately: $887 | €709

Summary


Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D.

An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Content


  • Executive Summary
    • A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis
  • Therapeutic Area Focus
    • Key product analysis and forecasting
    • Central Nervous System
    • Adderall/Adderall XR (mixed amphetamine salts)
    • Daytrana (methylphenidate)
    • Reminyl (galantamine)
    • Vyvanse (lisdexamphetamine dimesylate)
    • Human Genetic Therapies
    • Elaprase (idursulfase)
    • Replagal (agalsidase)
    • Gastrointestinal
    • Lialda/Mezavant (mesalamine)
    • Pentasa (mesalamine)
    • Renal
    • Dynepo (epoetin delta)
  • Operational Data
    • A wealth of background and detail
    • A full 5-year financial performance assessment
    • Key corporate events
    • Key agreements
    • Infrastructure
    • Subsidiaries and joint ventures